A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized13c-labeled pyruvate utilization as methods for detecting tumor response to treatment

Neoplasia

Volumn 11, Issue 6, 2009, Pages 574-582

  Witney, Timothy H ^a,b   Kettunen, Mikko I ^a,b   Day, Samuel E ^a,c   Hu, De En ^a,b   Neves, Andre A ^a,b   Gallagher, Ferdia A ^a,b   Fulton, Sandra M ^a   Brindle, Kevin M ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; LACTIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PYRUVIC ACID C 13; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CARBON NUCLEAR MAGNETIC RESONANCE; DIAGNOSTIC IMAGING; DRUG UPTAKE; ENZYME ACTIVITY; FEMALE; HYPERPOLARIZATION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LYMPHOMA; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 66449129568     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09254     Document Type: Article

References (39)

1. Brindle K (2008). New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8, 1-14.
2. Neves AA and Brindle KM (2006). Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta 1766, 242-261. (Pubitemid 46321458)
3. Weissleder R and Pittet MJ (2008). Imaging in the era of molecular oncology. Nature 452, 580-589.
4. Merrall NW, Plevin R, and Gould GW (1993). Growth-factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 5, 667-675. (Pubitemid 24023413)
5. Gatenby RA and Gillies RJ (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 891-899.
6. Czernin J and Phelps ME (2002). Positron emission tomography scanning: current and future applications. Annu Rev Med 53, 89-112. (Pubitemid 34177873)
7. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, and Schwaiger M (2003). Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21, 2651-2657. (Pubitemid 46606307)
8. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, et al. (2000). Positron emission tomography using [F-18]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18, 1689-1695. (Pubitemid 30220547)
9. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, et al. (2001). Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19, 3058-3065. (Pubitemid 32565444)
10. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, DeWolf Peeters C, et al. (2001). Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([F-18]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [F-18] FDG-PETa valid alternative to conventional diagnostic methods? J Clin Oncol 19, 414-419.
11. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, and Kuhn W (2005). Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 23, 7445-7453. (Pubitemid 46291806)
12. Takahashi N, Inoue T, Lee J, Yamaguchi T, and Shizukuishi K (2007). The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 72, 226-233.
13. Phelps ME and Mazziotta JC (1985). Positron emission tomography - human-brain function and biochemistry. Science 228, 799-809. (Pubitemid 15021439)
14. Zhuang HM, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li PY, Mozley PD, Rossman MD, Albelda SM, and Alavi A (2001). Dual time point F-18-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42, 1412-1417. (Pubitemid 32852620)
15. Strauss LG (1996). Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23, 1409-1415. (Pubitemid 26340597)
16. Weber WA (2005). Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46, 983-995. (Pubitemid 43733514)
17. Stahl A, Ott K, Schwaiger M, and Weber WA (2004). Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nuc Med Mol Imag 31, 1471-1479. (Pubitemid 39592766)
18. Diederichs CG, Staib L, Glatting G, Beger HG, and Reske SN (1998). FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39, 1030-1033. (Pubitemid 28270121)
19. Thie JA (2004). Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45, 1431-1434. (Pubitemid 47618494)
20. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, and Golman K (2003). Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA 100, 10158-10163. (Pubitemid 37071849)
21. 13C magnetic resonance imaging and spectroscopy. Nat Med 13, 1382-1387.
22. Darzynkiewicz Z, Bruno S, Delbino G, Gorczyca W, Hotz MA, Lassota P, and Traganos F (1992). Features of apoptotic cells measured by flow-cytometry. Cytometry 13, 795-808.
23. Bergmeyer HU, Grassl M, and Walter HE (1983). Hexokinase. In HU Bergmeyer (Ed.). Methods of Enzymatic Analysis. Weinheim-Deerfield Beach, FL-Basel: Verlag Chemie, pp. 222-223.
24. Schmitz JE, Kettunen MI, Hu DE, and Brindle KM (2005). 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn Reson Med 54, 43-50. (Pubitemid 40898395)
25. Aubin JE (1979). Autofluorescence of viable cultured mammalian cells. J Histochem 27, 36-43. (Pubitemid 9131769)
26. Ying WH, Alano CC, Garnier P, and Swanson RA (2005). NAD(+) as a metabolic link between DNA damage and cell death. J Neurosci Res 79, 216-223. (Pubitemid 40116438)
27. Cheng Z, Levi J, Xiong ZM, Gheysens O, Keren S, Chen XY, and Gambhir SS (2006). Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem 17, 662-669. (Pubitemid 43794375)
28. van Waarde A, Shiba K, de Jong JR, Ishiwata K, Dierckx RA, and Elsinga PH (2007). Rapid reduction of sigma(1)-receptor binding and F-18-FDG uptake in rat gliomas after in vivo treatment with doxorubicin. J Nucl Med 48, 1320-1326.
29. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, and Weber W (2006). Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12, 5659-5667. (Pubitemid 44629592)
30. Wieman HL, Wofford JA, and Rathmell JC (2007). Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 18, 1437-1446. (Pubitemid 46626638)
31. Widmann C, Gibson S, and Johnson GL (1998). Caspase-dependent cleavage of signaling proteins during apoptosis - a turn-off mechanism for anti-apoptotic signals. J Biol Chem 273, 7141-7147. (Pubitemid 28160387)
32. Zhou R, Vander Heiden MG, and Rudin CM (2002). Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res 62, 3515-3520. (Pubitemid 34651402)
33. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, and Poirier GG (1993). Specific proteolytic cleavage of poly(ADP-ribose) polymerase - an early marker of chemotherapy-induced apoptosis. Cancer Res 53, 3976-3985. (Pubitemid 23267698)
34. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, et al. (2003). (18)FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39, 2012-2020. (Pubitemid 37297757)
35. Cremerius U, Effert PJ, Adam G, Sabri O, Zimny M, Wagenknecht G, Jakse G, and Buell U (1998). FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 39, 815-822. (Pubitemid 28216730)
36. Barrington SF and O'Doherty MJ (2003). Limitations of PET for imaging lymphoma. Eur J Nuc Med Mol Imag 30, S117-S127. (Pubitemid 36735769)
37. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, Pratt B, Husband J, Flower M, and Ott R (1996). Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 14, 700-708. (Pubitemid 26085512)
38. Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, Enne W, Herz M, Nerl C, Garbrecht M, et al. (1998). Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 91, 4464-4471. (Pubitemid 28270292)
39. 13C 3D-MRSI following therapy in a mouse model of prostate cancer. Proc Int Soc Magn Reson Med 16, 888.